Roche peddles innovation cycle and predicts demise of peleton
This article was originally published in Scrip
Roche CEO Severin Schwan believes innovation will be the key to his company's future success in an increasingly challenging environment in both developed and emerging markets. Speaking at the company's investor day, Mr Schwan told fund managers and analysts that it is a strategy that is already paying dividends.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.